...A. We have biologic with 2 different technologies, antibodies, the next -- the new one entering the clinic is called -- going after [CALR]. B. And we have a partnership with Merus, and we also do internally bispecific antibodies where 2 of them are already in the clinic. C. The last one was the TGF-beta PD-1 bispecific. D. Going to the center in terms of clinical development, we have 2 franchisees and that's something that is relatively new in the past 4 years. E. And to the left, where we have now 3 centers for commercialization in North America, Canada and U.S.. For both oncology and dermatology, we have 7 approved product coming from our pipeline, 5 of them are commercialized by Incyte and 2 of them with partners. F. In Europe, where you have the 7 approved products and 4 of them by Incyte. G. And in Japan, where we are starting our commercial business with one product being commercialized by Incyte, pemigatinib and 3 of the other products approved in Japan with a partner. H. If you...
